14-HN-26-AZ (D4193C00001): A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Grants and Contracts Details

StatusFinished
Effective start/end date1/27/15 → 6/30/18

Funding

  • AstraZeneca Pharmaceuticals AB: $64,752.00